Synergistic Activity of Anti-GD2 Antibody and CD47-Blockade for Immunotherapy of Neuroblastoma and Osteosarcoma |
The Board of Trustees of the Leland Stanford Junior University / Robbie Majzner, MD |
'A' Award Grants |
2019 |
California |
Synergistic Differentiation Therapy in Neuroblastoma |
Duke University / Gerard Blobe, M.D./Ph.D |
Innovation Grants |
2015 |
North Carolina |
Synthetic gene expression regulator switches (SynGERS) expressed in CAR T cells to cure children with solid tumors |
Baylor College of Medicine / Andras Heczey, MD |
R Accelerated Award Grants |
2023 |
Texas |
Synthetic Gene Expression Regulatory Switches (SynGERS) for Improved CAR T Cell Function in Pediatric Solid Tumors |
Baylor College of Medicine / Leidy Diana Caraballo Galva, PhD |
Young Investigator Grants |
2023 |
Texas |
Targeted Combination Therapy to Sensitize High-Risk Acute Lymphoblastic Leukemia to Methotrexate via Restoration of Ikaros Tumor Suppression |
The Pennsylvania State University / Sinisa Dovat, MD/PhD & Chunhua Song, MD/PhD |
Innovation Grants |
2016 |
Pennsylvania |
Targeted Degradation of Proliferative Transcription Factors in Pediatric Cancers |
University of California at Santa Cruz / Seth Rubin, PhD |
Innovation Grants |
2017 |
California |
Targeted Hyperactivation of PI3K/AKT in B-cell malignancies |
Dana-Farber Cancer Institute / Vishal Khairnar, PhD |
Young Investigator Grants |
2019 |
Massachusetts |
Targeted Inhibition of Lin28/let-7 Binding to Treat Pediatric Malignancy |
Boston Children’s Hospital / George Q. Daley, MD/PhD |
Innovation Grants |
2016 |
Massachusetts |
Targeted Inhibition of Signaling Networks in Pediatric Glioblastoma Stem Cells |
University of California Berkeley / Erin Simonds, PhD |
Young Investigator Grants |
2013 |
California |
Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias |
National Cancer Institute / Andre Nussenzweig, Ph.D. |
Reach Grants |
2014 |
Maryland |